Eurofins Fact Sheet
Eurofins Scientific is an international life sciences company which provides a unique range of analytical testing services to clients across multiple industries. The Group believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
Eurofins Scientific was founded in 1987 with 10 employees to market the SNIF-NMRâ technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.
Today the Eurofins Group is a leading provider of analytical services with :
- an international network of 310 laboratories across 39 countries in Europe, North and South America and Asia-Pacific
- over 28,000 staff
- a portfolio of over 130,000 analytical methods
- more than 150 million assays performed each year to establish the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as carry out human diagnostic services.
Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins' sales have increased by 37% each year (in compound average) to over EUR 2.54 billion in 2016.
Between the Initial Public Offering on 24 October 1997 (€1.83) and 31 December 2016 (€405.00), Eurofins’ share price has multiplied by 221x, an annual average increase of 33% (against 4% for the SBF 120, 3% for the CAC 40 and 6% for the Nasdaq over the same period).
In 2015, Eurofins achieved its mid-term objective set in 2012 of generating EUR 2bn annual revenues by 2017, two years early, with EUR 2.24bn pro-forma revenues in 2015 (EUR 1.95bn on a reported basis). The Group’s ability to execute on its mid-term plan reflects the benefits of both past and ongoing investments to put together the most comprehensive portfolio of analytical methods and the most modern, state-of-the-art laboratory network that allows the Group to provide best-in-class analytical services to the markets it serves in the most efficient manner. Having consistently invested at higher rate than any of its large peers in the testing industry, Eurofins boasts a very modern, streamlined network of laboratories uniquely capable of providing high quality analyses at a reasonable cost. In 2016 alone, the Group added another 46,000m2 of world class laboratory surface to its network, and plans another 139,000m2 additional capacity between 2017 and 2018, to bring total modernized laboratory surface to 380,000m2.
Eurofins has undergone several intense investment phases previously. The first cycle saw Eurofins expand its technological portfolio and secure market leadership in food testing in several European countries; the second cycle expanded the Group’s geographical footprint and established the Group as a global reference in laboratory testing of food, the environment and pharmaceutical products. During this phase, investments in 18 start-ups, along with focused acquisitions, substantially increased the range of Eurofins’ offerings in its customers’ key markets around the world. Overall, those laboratories started up by Eurofins in new markets such as India, China, Brazil, Singapore and Eastern Europe now provide an increasingly important growth engine for the Group. Between 2014 and 2017, the Group has plans to deliver 76 start-up laboratories, bringing total number of start-ups launched over 10 years (2007-2017) to 110.
Over the years, Eurofins has developed many new analytical testing methods and has participated in, or led several R&D projects to find better ways to analyse food, the environment, and pharmaceutical products. More recently, the Group has also started to leverage its world-renowned genomics expertise in the area of specialty clinical diagnostics testing to provide new human diagnostic capabilities. Drawing on its world-class Competence Centres and its expertise, Eurofins is driving growth from its market-leading portfolio of tests, outsourcing agreements and through cross-selling opportunities across its world-wide laboratory network.
Eurofins is committed to supporting its clients’ objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate and supporting medical practitioners and patients with innovative diagnostic services. The Group intends to continue to develop and acquire the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
In February 2017, the Group announced its objective to achieve close to EUR 2.9bn and EUR 550m (at constant currency) of revenues and adjusted EBITDA respectively for the year, and from then on, to grow by about 11.3% per year over the medium term, including about EUR 200m per year from acquisitions, to reach revenues of EUR 4bn by 2020. In-line with this objective, Eurofins continues to position itself in markets where the Group sees current or potential tangible growth opportunities and intends to continue investing in its existing network, to maximize efficiencies, and ensure long-term profitability.
|Contact and Addresses|
Florian Heupel, Group Marketing
Pamela Antay, Investor Relations